Anbio Biotechnology reported total assets of $30.24M and total liabilities of $0.09M for the quarter ended Dec 2025. This balance sheet covers 4 quarters of results from Dec 2023 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2023 | Dec2024 | Jun2025 | Dec2025 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & EquivalentsCash & Equiv. | 9.69M | 11.76M | 5.35M | 7.77M |
| Short-term InvestmentsInvestments (Current) | 0.00M | 8.08M | 4.13M | |
| Cash & Current Investments | 9.69M | 11.76M | 13.43M | 11.90M |
| Receivables - NetNet Receivables | 1.88M | 1.06M | 3.72M | 3.66M |
| Receivables - OtherOther Receivables | 948.00 | |||
| Receivables | 1.88M | 1.06M | 3.72M | 3.66M |
| Prepaid Assets | 3.77M | 5.68M | 10.17M | 14.08M |
| Current Assets | 15.75M | 18.53M | 27.68M | 30.24M |
| Non-Current Assets | ||||
| Other Non-Current Assets | 0.04M | 0.39M | ||
| Non-Current Assets | 0.06M | 0.39M | ||
| Assets | 15.81M | 18.92M | 27.68M | 30.24M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payables | 0.83M | 1.63M | 0.06M | |
| Payables | 0.83M | 1.63M | 0.06M | |
| Accumulated Expenses | 0.13M | 0.10M | 0.09M | |
| Other Accumulated Expenses | 0.17M | 0.10M | 0.07M | 0.09M |
| Total Current Liabilities | 0.99M | 1.73M | 0.13M | 0.09M |
| Non-Current Liabilities | ||||
| Preferred Stock Liabilities | 0.00M | 0.00M | ||
| Total Liabilities | 0.99M | 1.73M | 0.13M | 0.09M |
| Shareholder's Equity | ||||
| Common Equity | 14.82M | 17.19M | 27.55M | 30.16M |
| Liabilities and Shareholders Equity | 15.81M | 18.92M | 27.68M | 30.24M |
| Retained Earnings | 14.80M | 17.17M | 20.97M | 23.58M |
| Preferred Shares | 0.00M | 0.00M |